These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 9364215

  • 1. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
    Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M.
    Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
    [Abstract] [Full Text] [Related]

  • 2. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity.
    Aoki K, Yoshida T, Sugimura T, Terada M.
    Cancer Res; 1995 Sep 01; 55(17):3810-6. PubMed ID: 7641198
    [Abstract] [Full Text] [Related]

  • 3. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 4. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
    Nakano M, Aoki K, Matsumoto N, Ohnami S, Hatanaka K, Hibi T, Terada M, Yoshida T.
    Mol Ther; 2001 Apr 07; 3(4):491-9. PubMed ID: 11319909
    [Abstract] [Full Text] [Related]

  • 5. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
    Zhu ZW, Friess H, Wang L, Bogardus T, Korc M, Kleeff J, Büchler MW.
    Clin Cancer Res; 2001 Jan 07; 7(1):105-12. PubMed ID: 11205897
    [Abstract] [Full Text] [Related]

  • 6. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
    Ohnami S, Matsumoto N, Nakano M, Aoki K, Nagasaki K, Sugimura T, Terada M, Yoshida T.
    Cancer Res; 1999 Nov 01; 59(21):5565-71. PubMed ID: 10554036
    [Abstract] [Full Text] [Related]

  • 7. The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma.
    Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, Spitz D, Oberley LW.
    Cancer Res; 2003 Mar 15; 63(6):1297-303. PubMed ID: 12649190
    [Abstract] [Full Text] [Related]

  • 8. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA.
    Mol Cancer Res; 2005 Jul 15; 3(7):413-23. PubMed ID: 16046552
    [Abstract] [Full Text] [Related]

  • 9. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.
    Miura Y, Ohnami S, Yoshida K, Ohashi M, Nakano M, Ohnami S, Fukuhara M, Yanagi K, Matsushita A, Uchida E, Asaka M, Yoshida T, Aoki K.
    Cancer Lett; 2005 Jan 31; 218(1):53-62. PubMed ID: 15639340
    [Abstract] [Full Text] [Related]

  • 10. G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells.
    Cogoi S, Quadrifoglio F, Xodo LE.
    Biochemistry; 2004 Mar 09; 43(9):2512-23. PubMed ID: 14992588
    [Abstract] [Full Text] [Related]

  • 11. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K, Chijiiwa K, Torato N, Kinoshita M, Tanaka M.
    Am J Gastroenterol; 2000 Aug 09; 95(8):1939-45. PubMed ID: 10950039
    [Abstract] [Full Text] [Related]

  • 12. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
    Lebedeva IV, Su ZZ, Sarkar D, Gopalkrishnan RV, Waxman S, Yacoub A, Dent P, Fisher PB.
    Oncogene; 2005 Jan 20; 24(4):585-96. PubMed ID: 15580305
    [Abstract] [Full Text] [Related]

  • 13. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
    Mohiuddin M, Chendil D, Dey S, Alcock RA, Regine W, Mohiuddin M, Ahmed MM.
    Anticancer Res; 2002 Jan 20; 22(2A):825-30. PubMed ID: 12014658
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW.
    Cancer Res; 2006 Oct 01; 66(19):9736-43. PubMed ID: 17018633
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
    Seiden-Long IM, Brown KR, Shih W, Wigle DA, Radulovich N, Jurisica I, Tsao MS.
    Oncogene; 2006 Jan 05; 25(1):91-102. PubMed ID: 16158056
    [Abstract] [Full Text] [Related]

  • 16. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
    Kanovsky M, Michl J, Botzolaki G, Morin J, Kovac C, Chung DL, Chie L, Friedman FK, Pincus MR.
    Cancer Chemother Pharmacol; 2003 Sep 05; 52(3):202-8. PubMed ID: 12783204
    [Abstract] [Full Text] [Related]

  • 17. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
    Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N.
    J Surg Res; 1996 Dec 05; 66(2):125-30. PubMed ID: 9024823
    [Abstract] [Full Text] [Related]

  • 18. [The study of the effect of antisense oligonucleotide specific to K-ras point mutation on human pancreatic carcinoma cell PC-2].
    Wang YX, Gao L, Ji ZZ.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 01; 43(21):1387-90. PubMed ID: 16318775
    [Abstract] [Full Text] [Related]

  • 19. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
    Hatanaka K, Suzuki K, Miura Y, Yoshida K, Ohnami S, Kitade Y, Yoshida T, Aoki K.
    J Gene Med; 2004 Oct 01; 6(10):1139-48. PubMed ID: 15452878
    [Abstract] [Full Text] [Related]

  • 20. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K, Park S, Ewton DZ, Friedman E.
    Cancer Res; 2007 Aug 01; 67(15):7247-55. PubMed ID: 17671193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.